Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression imbalance [1] Group 1 - The clinical trial application for GR2301 injection has been approved, marking a significant milestone for the company [1] - GR2301 injection is designed to inhibit the downstream IAK-STAT signaling pathway by blocking IL-15 interactions, which is crucial for treating autoimmune diseases [1] - As of the announcement date, there are no approved antibody drugs targeting IL-15 globally, indicating a potential market opportunity for the company [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression dysregulation [1] Group 1 - The clinical trial application for GR2301 injection has been approved [1] - GR2301 injection is developed independently by the company [1] - The mechanism of GR2301 involves blocking IL-15 from binding to its receptors, thereby inhibiting the downstream IAK-STAT signaling pathway [1]